Kawakami, H., Hironaka, S., Esaki, T., Chayama, K., Tsuda, M., Sugimoto, N., . . . Muro, K. (2021). An Investigator-Initiated Phase 2 Study of Nivolumab Plus Low-Dose Ipilimumab as First-Line Therapy for Microsatellite Instability—High Advanced Gastric or Esophagogastric Junction Cancer (NO LIMIT, WJOG13320G/CA209-7W7). Cancers (Basel).
शिकागो स्टाइल उद्धरणKawakami, Hisato, et al. "An Investigator-Initiated Phase 2 Study of Nivolumab Plus Low-Dose Ipilimumab As First-Line Therapy for Microsatellite Instability—High Advanced Gastric or Esophagogastric Junction Cancer (NO LIMIT, WJOG13320G/CA209-7W7)." Cancers (Basel) 2021.
एमएलए उद्धरणKawakami, Hisato, et al. "An Investigator-Initiated Phase 2 Study of Nivolumab Plus Low-Dose Ipilimumab As First-Line Therapy for Microsatellite Instability—High Advanced Gastric or Esophagogastric Junction Cancer (NO LIMIT, WJOG13320G/CA209-7W7)." Cancers (Basel) 2021.